Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Übungsbasierte Schlaganfall-Rehabilitation

6. Oktober 2026 aktualisiert von: VA Office of Research and Development

Den Rehabilitationsmotor ankurbeln: Aerobic-Übungen als Treibstoff für Verhaltensverbesserungen bei Schlaganfällen

Stroke is a leading cause of disability in the U.S. and many Veteran stroke survivors live with severe disability. Despite recent advances in rehabilitation treatments many stroke survivors have persistent physical and mental difficulties such as reduced physical and cognitive function and depression. Developing innovative treatments that address these problems is necessary to improve long-term outcomes for stroke survivors. Aerobic exercise (AEx) can improve physical and cognitive function, and reduce depression. Additionally, AEx may enhance physical rehabilitation by making the brain more receptive to, and consequently improving the response to an intervention. Therefore, combining AEx with physical rehabilitation has the potential to improve multiple aspects of stroke recovery. This study will examine the effect of combining AEx with physical rehabilitation on physical and mental function in stroke survivors. By gaining a better understanding of the effects of this combined intervention the investigators aim to advance the rehabilitative care of Veteran stroke survivors.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The purpose of this project is to examine the 'priming' effect of aerobic exercise (AEx) on a motor rehabilitation intervention for chronic stroke survivors. Aerobic exercise (AEx) promotes numerous functional, cognitive, and psychological benefits. For example, AEx has demonstrated positive effects on physical performance, cardiovascular health, global cognition, executive function and depressive symptoms in neurologically healthy individuals as well as survivors of stroke. Importantly, emerging evidence also supports the use of AEx as a priming tool to enhance motor outcomes following targeted rehabilitation. Potential mechanisms underlying the priming effects of AEx include increases in circulating brain-derived neurotrophic factor (BDNF) and corticomotor excitability (CME). The wide-ranging behavioral and physiological benefits of AEx ideally suit it to serve as an adjunctive primer to stroke rehabilitation programs. The investigators' conceptual framework involves priming with AEx prior to targeted motor rehabilitation to enhance the 'neuroplastic environment" and make the brain more amenable to adaptation, thereby enhancing response to rehabilitation. Specifically, the investigators propose to pair AEx with an upper extremity virtual reality rehabilitation game called Duck Duck Punch (DDP) as the platform for examining the adjunctive potential of AEx. To evaluate the priming effects of AEx, chronic stroke survivors will be randomly assigned to receive 8 weeks (3 sessions/week) of DDP preceded by either 15 minutes of AEx (AEx+DDP) or a stretching control (CON+DDP). This design will address the following specific aims:

Aim 1: Evaluate the priming effects of AEx on a motor rehabilitation intervention for chronic stroke survivors.

Aim 2: Quantify the effects of AEx priming on biomarkers of neuroplasticity.

By stimulating the neuroplastic environment the investigators aim to enhance the response to motor rehabilitation. However, additional stroke sequelae (eg. cognitive and psychological function) may influence the magnitude of change in motor function. Depression and impaired cognitive function can negatively influence stroke recovery outcomes, and are characterized by reduced neuroplastic potential and BDNF. Subsequently, subjects with depression or cognitive impairment are often excluded from rehabilitation trials. Thus, data that describes the relationship of multiple domains of stroke recovery as well as the neurobiological underpinnings of the response to rehabilitation will illuminate this gap in the literature and generate the formation of new hypotheses for future study.

Exploratory Aim: Examine the influence of cognitive and psychological function on motor response to AEx+DDP.

The primary goal of this proposal is to provide foundational support to develop AEx as an adjunctive primer to rehabilitation. The data generated will inform the development of additional AEx-based interventions for individuals following stroke as well as other neurological or neuropsychiatric conditions.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

36

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • South Carolina
      • Charleston, South Carolina, Vereinigte Staaten, 29401-5703
        • Ralph H. Johnson VA Medical Center, Charleston, SC

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

50 Jahre bis 90 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • experienced unilateral stroke at least 6 months prior
  • voluntarily shoulder flexion of the affected arm 20 degrees with simultaneous elbow extension 10 degrees
  • moderate arm movement impairment (UE Fugl-Meyer Assessment > 21 but < 52 points
  • passive range of motion in paretic shoulder, elbow, wrist, thumb and fingers within 20 degrees of normal
  • ability to communicate as per the therapists' judgement at baseline testing
  • ability to complete and pass an exercise tolerance test
  • Box & Block test score of at least 3 blocks in 60 seconds with the affected arm

Exclusion Criteria:

  • lesion in brainstem/cerebellum as these may interfere with visual-perceptual/cognitive skills needed for motor re-learning
  • presence of other neurological disease that may impair motor learning skills
  • orthopedic condition or impaired corrected vision that alters reaching ability (e.g., prior rotator cuff tear without full recovery)
  • paretic arm pain that interferes with reaching
  • unable to understand or follow 3-step directions
  • severe cognitive impairment (Montreal Cognitive Assessment (MoCA) score 17)
  • severe aphasia
  • inability to read English
  • history of congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during Activities of daily living (ADL's)
  • Severe hypertension with systolic >200 mmHg and diastolic >110 mmHg at rest
  • History of chronic obstructive pulmonary disease (COPD) or oxygen dependence
  • History of deep vein thrombosis (DVT) or pulmonary embolism within 6 months
  • Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions
  • UBACC score < 15; and for brain stimulation procedures only:
  • electronic or metallic implants
  • history of seizures
  • women of child bearing potential

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Aerobic exercise (AEx) + upper extremity rehabilitation

Subject will receive a total of 24 intervention sessions. In each session, subjects will perform 15 minutes of AEx followed by 200 repetitions of an upper extremity rehabilitation program.

Experimental: Stretching (CON) + upper extremity rehabilitation

Subjects will perform 15 minutes of lower extremity stretching. Following lower extremity stretching subjects will receive 200 repetitions of DDP.

Duck Duck Punch (DDP) is an interactive computer game deliberately designed to enhance UE movement quality via individualized progressive movement practice. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to "punch" virtual ducks. The goal 'dose' of DDP will be 200 repetitions.

Andere Namen:
  • DDP

Subjects will perform 15 minutes of lower extremity stretching. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.

Andere Namen:
  • CON

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from baseline upper extremity impairment assessed by the Fugl Meyer Upper Extremity Assessment (FMA-UE)
Zeitfenster: Approximately 8 weeks

The FMA-UE is a 33-item measure of UE impairment; however, the 3 items testing reflex response will not be administered because they do not measure a voluntary movement construct. Each item will be scored on a 3-point rating scale (0=unable, 1=partial 2=near normal performance), item ratings will be summed and reported out of 60 points so that larger numbers indicate greater UE motor ability.

Approximately 8 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from baseline upper extremity motor function assessed by the Wolf Motor Function Test (WMFT)
Zeitfenster: Approximately 8 weeks

The WMFT is a 15-item measure of upper extremity functional ability. Performance of each item will be timed (seconds) and the average time to perform items will be reported so that lower values indicate greater upper extremity function.

Approximately 8 weeks
Change from baseline locomotor function assessed by self-selected walking (SSWS) speed and six-minute walk test (6MWT)
Zeitfenster: Approximately 8 weeks

Locomotor function will be assessed with SSWS and the 6MWT. For SSWS, subjects will walk on a 14 feet long gait mat (GaitRite). For 6 minute walk test (MWT) subjects will walk in an unobstructed hallway for six minutes. These assessments will provide measures of mobility and functional capacity.

Approximately 8 weeks
Change from baseline health related quality of life assessed by the Stroke Impact Scale (SIS)
Zeitfenster: Approximately 8 weeks

The SIS assesses physical function as well as other dimension of health-related quality of life: emotion, communication, memory & thinking, and social role function. Specifically, the Hand and Perceived Recovery subsets of the SIS will be used to assess the effect of the intervention on 'real world' arm use. The SIS-hand consists of 5-items regarding difficulty of paretic hand use during everyday tasks during the previous two weeks. Items will be rated on a 5-point scale (5=not difficult, 1=cannot do) and reported as an average item rating. The SIS-recovery subtest is a single-item in which the participant rates his/her perceived post-stroke recovery from 0%-100% recovered.

Approximately 8 weeks
Change from baseline depressive symptoms assessed by the Geriatric Depression Scale (GDS)
Zeitfenster: Approximately 8 weeks

The GDS-short form is a 15-item self-report questionnaire that assesses the presence of depressive symptomology in elderly individuals. Questions are in yes/no format with a maximum score of. Scores greater than 5 indicate probable depression. This assessment will provide information regarding the presence of depressive of symptoms and the potential impact such symptoms may have on response to the proposed intervention.

Approximately 8 weeks
Change from baseline cognitive function assessed by National Institutes of Health Toolbox - Cognition Battery (NIHTB-CB)
Zeitfenster: Approximately 8 weeks

The NIHTB-CB is a brief (~30 minutes) and comprehensive evaluation of multiple domains of cognitive function including executive function, working memory, episodic memory, processing speed, and language. There are seven subtests (picture vocabulary, oral reading recognition, picture sequence memory test, pattern comparison, list sorting, flanker, dimensional change card sort) within the NIHTB, which can be used to generate composite scores in fluid and crystallized cognitive function. This provides an opportunity to gain objective insight into granular and global changes in cognitive function. The NIHTB-CB has been validated in stroke.

Approximately 8 weeks
Change from baseline peripheral plasma and serum brain-derived neurotrophic factor (BDNF)
Zeitfenster: Approximately 8 weeks

Blood specimens will be obtained immediately before and after AEx or CON on three separate occasions (intervention sessions 1, 13, and 24). Briefly, an intravenous catheter will be placed in a superficial forearm vein at the beginning of the priming session and will be maintained patent using an isotonic saline solution. Baseline blood samples will be drawn immediately before the priming session (AEx or CON) commences. Immediate post-AEx or CON, blood samples will be taken within sixty seconds of priming session completion while the participant remains seated in the cycle ergometer.

Approximately 8 weeks
Change from baseline neuroplastic potential
Zeitfenster: Approximately 8 weeks

Subjects will have neuroplastic potential assessed with a plasticity-inducing paradigm called paired associative stimulation (PAS). Briefly, PAS utilizes a repeated and timed peripheral nerve stimulation combined with transcranial magnetic stimulation (TMS) of the contralateral motor cortex to induce motor cortex plasticity. Prior to- and after PAS, motor cortex plasticity will be assessed via motor evoked potentials (MEP) which are obtained by single pulse TMS and electromyography (EMG) of the contralateral abductor pollicis brevis muscle. The relative change in mean peak-to-peak amplitude (measured in millivolts) of twenty MEP's obtained prior to PAS and following PAS will be used as the index of neuroplastic potential. The change in this index 8 weeks from baseline will indicate changes in neuroplastic potential.

Approximately 8 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Ryan E Ross, PhD, Ralph H. Johnson VA Medical Center, Charleston, SC

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Juli 2021

Primärer Abschluss (Tatsächlich)

30. September 2026

Studienabschluss (Geschätzt)

31. Januar 2027

Studienanmeldedaten

Zuerst eingereicht

26. April 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. Mai 2021

Zuerst gepostet (Tatsächlich)

7. Mai 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • B3540-W
  • 5IK2RX003540-04 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .